Plain-English translation of NCT07584122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The PrEPOUT Rio Study is testing a new way to provide oral pre-exposure prophylaxis (PrEP)—a daily medication that prevents HIV infection—to people who need it most in Rio de Janeiro. Instead of going to traditional hospitals or clinics, you would receive the medication and support through community organizations and mobile health units in your neighborhood. The study also uses phone and text-based support to help people stay on the medication and engaged in their care.
Many people in underserved communities face barriers to getting HIV prevention medication, such as distance to clinics, cost, stigma, or not knowing where to go. This study exists to find out whether bringing this treatment directly to communities—in places people already trust—can help more people access it and stick with it long-term.
You likely qualify if…
You likely don't qualify if…
You would visit a community-based clinic or mobile health unit where you'll receive an HIV test, counseling, and—if you're HIV-negative and interested—you can start the daily medication. The study team provides ongoing support through in-person visits, phone consultations, and text messages to help you take the medication consistently and stay engaged in your care. If you test positive for HIV at any point, you'll be referred to treatment services within the public health system.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Brazil